Charles E. Ford

powered by
COS Expertise®
University of Texas Health Science Center at Houston
School of Public Health
Biometry
Associate ProfessorAppointed: 1995
Professional Headshot of Charles E. Ford

Mailing Address

1200 Herman Pressler St.
University of Texas - Houston Health Science Center
Room E-827 RAS
Houston, Texas 77030
United States

Contact Information

Phone: (713) 500-9513
Fax: (713) 500-9530
ford@sph.uth.tmc.edu

Qualifications

Ph.D., University of Texas - Houston Health Science Center, School of Public Health, Biometry, 1986.
M.S., University of Texas - Houston Health Science Center; School of Public Health, Biometry, 1981.
B.S., University of Central Oklahoma; Edmond, OK, Mathematics, 1969.

Expertise and Research Interests

Research interests:
Geometric methods in multivariate analysis;
statistical computing;
design, conduct and analysis of multicenter clinical trials;
multiple endpoints analysis;
longitudinal data analysis;
polychotomous logistic regression analysis;
cardiovascular research;
statistical genetics.

Current research projects include:
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT);
Genetics of Hypertension Associated Treatment (GenHAT);
Genetics of cardiovascular disease;
Geometric methods in multivariate analysis;
Polychotomous logistic regression analysis;
Analytical methods for multiple outcomes in clinical trials;
Management and analysis of clinical trial data;
Clinical trial quality control.

Other Expertise

Academic Experience:
Honors & Awards:
Fellow, American Heart Association Council on Prevention and Epidemiology
Outstanding Scholarship Award, UT-HHSC, 1994;
Outstanding Achievement in Sponsored Research Award, UT-HHSC, 1994
Outstanding Faculty Award, UT-HHSC, 1993

Committees:
NIDDK External Advisory Committee for The African-American Study of Kidney Disease and Hypertension (AASK);
Academic Computing Committee, UT-HHSC;
Biometry Program Admissions Committee, UT-HSPH;
Disease Control Admissions Committee, UT-HSPH;
Scientific & Educational Programs Committee of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT);
Quality Control Committee of ALLHAT

Advisor:
American Heart Association, Council on Epidemiology

Keywords

COS Keywords:

Biostatistics, Cardiovascular Diseases, Clinical Trial, Hypertension, Information Management, Information Science Or Systems.

Additional Terms:

Biostatistician, Cardiovascular Disease, Clinical Trial Methodology, Genetics of Hypertension, Hypertension, Information Management, Multivariate Methods, Statistical Computing.

Memberships

American Heart Association
American Statistical Association
Houston Area Chapter of the American Statistical Association
Institute of Mathematical Statistics
International Biometric Society
Society for Clinical Trials
Society for Epidemiologic Research

Previous Positions

1991-1998, Co-Director, Conference on Career Opportunities in Public Health for Mathematics and Science Majors
1991-1995, Prospective Study of Blood Pressure and ESRD, Principal Investigator
1986-1995, Hypertension Detection and Follow-up Program, Co-Principal Investigator
1978-1986, Coordinating Center for Clinical Trials, UT School of Public Health, Biostatistician
1974-1978, Coordinating Center for Clinical Trials, UT School of Public Health, Systems Analyst III/Director of Computer Programming
1986-1995, The University of Texas-Houston School of Public Health, Assistant Professor of Biometry

Funding Received

  • National Institutes of Health (NIH): Genetics of Hypertension Associated Treatment (GenHAT), $4,942,610, Sep 1, 1999 to Aug 31, 2004.
  • Johns Hopkins University: A Prospective Study of Blood Pressure and ESRD, $69,750, June 1991 to May 1995.
  • Bureau of Health Professions, U.S Public Health Service: Training Grant for Career Opportunities in Biostatistics and Public Health for Science Majors (OBPH), $80,000, July 1991 to June 1995.
  • Merck Research Laboratories: Renal Cell Carcinoma in Patients Receiving Antihypertensive Pharmacologic Treatment, $3,000, Jan. 1994 to Dec. 1994.
  • National Institutes of Health (NIH): Extended Analysis in the Hypertension Detection and Follow-up Program (HDFP) -- Risks and Benefits, $727,358, Feb. 1986 to Feb. 1995.
  • National Institutes of Health (NIH): Clinical Trials Center for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), $86,000,000, Aug. 1993 to Aug. 2002.

Publications

  • Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black RH, Hamilton BP, Holland J, Mwachuku C, Papademetriou V, Probstfield J, Wright JT, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, for ALLHAT Collaborative Research Group, Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Herat Attack Trial (ALLHAT), Journal of Clinical Hypertension, In Press, 2002
  • Gorham RA, Emery RJ, Ford CE, Cooper SP, Statistical validation of a commonly used method for personnel dosimetry issuance determinations, Health Physics Journal, In Press, 2002
  • Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H, Pharmacogenetic approaches ro hypertension therapy: Design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study, Nature Pharmacogenetics, 2, 309-317, 2002
  • Grimm RH, Margolis KL, Papademetriou V, Cushman WC, Ford CE, Bettencourt J, Alderman MH, Basile JN, Black HR, DeQuattro V, Echfeldt J, Hawkins CM, Proschan M, for the ALLHAT Collaborative Research Group, Baseline characteristics of the 42,448 high risk hypertensives enrolled in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Hypertension, 37, 19-27, 2001
  • Pressel SL, Davis BR, Wright JT, Geraci TS, Kingry C, Ford CE, Piller LB, Bettencourt J, Kimmel B, Lusl C, parks H, Simpson LM, Nwachuku C, Furberg CD, for the ALLHAT Collaborative Research Group, Operational aspects of terminaing the doxazosin arm of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Controlled Clinical Trials, 22, 29-41, 2001
  • Cooksley CD, Hwang LY, Ford CE, HIV and cancer: Community-based analysis of trends and registry linkage, Journal of Registry Management, 28, 82-87, 2001
  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 283, 1967-1975, 2000
  • Djojonegoro BM, Aday LA, Williams AF, Ford CE, Area income as a predictor of preventable hospitalizations in the Harris County Hospital District, Houston, Texas Medicine, 96, 58-62, 2000
  • Cooksley CD, Hwang LY, Waller DK, Ford CE, HIV-related malignancies: community-based study using linkage of cancer registry and HIV registry data, International Journal of STD and AIDS, 10, 795-802, 1999
  • Proschan M, Davis B, Cutler J, Ford C, Furberg C, Grimm R, Oparil S, ALLHAT and calcium channel blockers. ALLHAT Research Group [letter; comment], American Journal of Hypertension, 10(1), 142-3, January 1997 Abstract
  • Davis B R, Cutler J A, Gordon D J, Furberg C D, Wright J T Jr, Cushman W C, Grimm R H, LaRosa J, Whelton P K, Perry H M, Alderman M H, Ford C E, Oparil S, Francis C, Proschan M, Pressel S, Black H R, Hawkins C M, Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group, American Journal of Hypertension, 9(4 Pt 1), 342-60, April 1996 Abstract
  • Klag M J, Whelton P K, Randall B L, Neaton J D, Brancati F L, Ford C E, Shulman N B, Stamler J, Blood pressure and end-stage renal disease in men., New England Journal of Medicine, 334(1), 13-8, 4 Jan 1996 Abstract
  • Walker WG, Ford C, At risk nephrons and the decline in renal function in response to treatment of hypertension, Transactions of the American Clinical and Climatological Association, 107, 134-145, 1995
  • Tyroler H A, Ford C E, Serum cholesterol and coronary heart disease risk in female and older hypertensives. The experience under usual community care in the Hypertension Detection and Follow-up Program., Annals of Epidemiology, 2(1-2), 155-60, January 1992 Abstract
  • Stamler R, Ford C E, Stamler J, Why do lean hypertensives have higher mortality rates than other hypertensives? Findings of the Hypertension Detection and Follow-up Program., Hypertension, 17(4), 553-64, April 1991 Abstract
  • Cooper S P, Ford C E, Hardy R J, Davis B R, Hawkins C M, Labarthe D R, Results of trials reporting a J-shaped relation between achieved blood pressure and incidence of coronary heart disease [letter; comment], American Journal of Hypertension, 3(9), 733-4, September 1990 Abstract
  • Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA, The prognostic value of serum creatinine and the effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-up Program, Hypertension, 13(Supplement I), 80-93, 1989
  • HDFP Cooperative Group, Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program, JAMA, 259, 2113-2122, 1988
  • Ford CE, Langford HG, Palmer MJ, Recruitment in the Hypertension Detection and Follow-up Program, Controlled Clinical Trials, 8(4 Suppl), 54S-67S, December 1987 Abstract
  • Schneider KA, Heyden S, Ford C, Failure to reduce cholesterol as explanation for the limited efficacy of antihypertensive treatment in the reduction of CHD. Evidence from the HDFP, Nefron, 47(Supplement 1), 104-107, 1987
  • Davis BR, Ford CE, Remington RD, Stamler R, Hawkins CM, The HDFP design, methods, and baseline characteristics and blood pressure response of the study population, Progress in Cardiovascular Disease, 29(Supplement 1), 11-28, 1986
  • HDFP Cooperative Group, Results and implications of the Hypertension Detection and Follow-up Program, Progress in Cardiovascular Disease, 29(Supplement 1), 1-124, 1986
  • Curb JD, Ford C, Pressel S, Palmer M, Babcock C, Hawkins CM, Ascertaining vital status through the National Death Index and the Social Security Administration, American Journal of Epidemiology, 121, 754-766, 1985
  • Maxwell MH, Ford CE, Cardiovascular morbidity and mortality in HDFP patients 50-69 years old at entry, Journal of Cardiovascular Pharmacology, 7(Supplement 2), 5-9, 1985
  • HDFP Cooperative Group, Mortality findings for stepped-care and referred-care participants in the HDFP, stratified by other risk factors, Preventive Medicine, 14, 312-335, 1985
  • HDFP Cooperative Group, Five-year findings of the HDFP. Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy, Hypertension, 7, 105-112, 1985
  • HDFP Cooperative Group, The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline: the HDFP experience, Circulation, 70, 996-1003, 1984
  • HDFP Cooperative Group, Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. Five-year findings of the HDFP, Hypertension, 6(Supplement I), 198-206, 1984
  • Curb JD, Ford C, Hawkins CM, Smith EO, Zimbaldi N, Carter B, Cooper C, A coordinating center in a clinical trial: the Hypertension Detection and Followup Program, Controlled Clinical Trials, 4(3), 171-86, September 1983 Abstract
  • HDFP Cooperative Group, The Hypertension Detection and Follow-up Program. Baseline characteristics of the enumerated, screened, and hypertensive participants, Hypertension, 5(Supplement IV), 1-200, 1983
  • HDFP Cooperative Group, Five-year findings of the Hypertension Detection and Follow-up Program. III. Reduction in stroke incidence among persons with high blood pressure, JAMA, 247, 633-638, 1982

Profile Details

Last Updated: 12/2/2002

COS Expertise ID #303615
Reference this profile directly: http://myprofile.cos.com/fordc15